Related Experiment Videos
Angiogenesis in myelodysplastic syndromes
G Pruneri1, F Bertolini, D Soligo
1Second Division of Pathology, IRCCS Maggiore Hospital, Milan, Italy.
British Journal of Cancer
|December 22, 1999
Summary
Myelodysplastic syndromes (MDS) show increased blood vessel growth compared to healthy controls, correlating with disease progression. Vascular endothelial growth factor (VEGF) expression is notable in megakaryocytes within MDS and leukemia.
Area of Science:
- Hematology
- Oncology
- Angiogenesis research
Background:
- Solid tumor growth relies on angiogenesis, but its role in hematological malignancies like myelodysplastic syndromes (MDS) is less understood.
- Investigating angiogenesis in MDS is crucial for understanding disease progression and potential therapeutic targets.
Purpose of the Study:
- To compare bone marrow microvessel density (MVD) in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative disorders (MPD) against controls.
- To evaluate the expression of vascular endothelial growth factor (VEGF) in these patient groups to understand its role in angiogenesis.
Main Methods:
- Immunohistochemistry was used to assess bone marrow microvessel density (MVD) in trephine biopsies.
- VEGF expression was evaluated using immunohistochemistry in biopsies from controls, MDS, AML, and MPD patients.
Main Results:
- MDS patients exhibited significantly higher MVD compared to controls and infectious disease patients, but lower than AML and MPD patients.
- Specific MDS subtypes (RAEB-t, CMML, fibrosis) showed higher MVD than others (RA, RARS, RAEB).
- VEGF expression was prominent in megakaryocytes but less so in blasts and other cell types within the studied samples.
Conclusions:
- The study indicates a correlation between increased angiogenesis and the progression of MDS towards leukemia.
- Further research is needed to elucidate the regulatory mechanisms of neovascularization in MDS and leukemia.